Dashboard
Manage Tickers

ASNDAscendis Pharma A/S

Nasdaq ascendispharma.com


$ 136.01 $ 6.40 (4.95 %)    

Tuesday, 25-Jun-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 135.79
$ 133.65
$ 0.00 x 0
$ 0.00 x 0
$ 133.58 - $ 138.03
$ 85.08 - $ 161.00
629,131
na
7.84B
$ 0.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

td-cowen-upgrades-ascendis-pharma-to-buy-raises-price-target-to-175
TD Cowen Upgrades Ascendis Pharma to Buy, ...
06/25/2024 11:35:59

TD Cowen analyst Yaron Werber upgrades Ascendis Pharma (NASDAQ:ASND) from Hold to Buy and raises the price target from $156 ...

ascendis-reports-presentation-of-data-from-phase-2-accomplish-trial-of-transcon-cnp-navepegritide-in-children-aged-2-to-10-years-old-with-achondroplasia-says-data-show-significant-improvements-in-well-being
Ascendis Reports Presentation Of Data From...
06/24/2024 20:48:01

The data showed that patients treated for one year at the pivotal 100μg/kg/week dose demonstrated significant improvements in w...

ascendis-pharma-to-present-new-data-and-updated-results-from-phase-12-il-believe-trial-at-asco-2024
Ascendis Pharma To Present New Data And Up...
06/03/2024 20:05:41

-  40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated...

if-you-invested-100-in-this-stock-15-years-ago-you-would-have-4100-today
If You Invested $100 In This Stock 15 Year...
05/31/2024 20:30:22

stifel-initiates-coverage-on-ascendis-pharma-with-buy-rating-announces-price-target-of-200
Stifel Initiates Coverage On Ascendis Phar...
05/31/2024 10:03:41

Stifel analyst Alex Thompson initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Targe...

asnd---analyzing-ascendis-pharmas-short-interest
(ASND) - Analyzing Ascendis Pharma's Short...
05/28/2024 14:00:26

100-invested-in-this-stock-10-years-ago-would-be-worth-6500-today
$100 Invested In This Stock 10 Years Ago W...
05/17/2024 20:00:34

morgan-stanley-maintains-equal-weight-on-ascendis-pharma-raises-price-target-to-140
Morgan Stanley Maintains Equal-Weight on A...
05/16/2024 16:00:50

Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and raises the price targe...

fda-pushes-review-date-for-ascendis-pharmas-hormone-disorder-candidate-by-three-months
FDA Pushes Review Date For Ascendis Pharma...
05/15/2024 15:57:08

Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August ...

cantor-fitzgerald-reiterates-overweight-on-ascendis-pharma-maintains-173-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/15/2024 12:27:24

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.

fda-extends-review-period-for-ascendis-pharmas-transcon-pth-for-adults-with-hypoparathyroidism
FDA Extends Review Period For Ascendis Pha...
05/14/2024 18:37:24

Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024

ascendis-pharma-announces-2-year-results-from-a-post-hoc-analysis-of-their-phase-3-pathway-trial-demonstrating-sustained-improvements-in-renal-function-in-adults-with-chronic-hypoparathyroidism-treated-with-transcon-pth
Ascendis Pharma Announces 2-Year Results F...
05/13/2024 12:37:16

Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway ...

ascendis-pharma-as-clinical-and-quality-of-life-data-for-transcon-pth-treated-adults-with-chronic-hypoparathyroidism-to-be-presented-at-ece-2024
Ascendis Pharma A/S Clinical And Quality-O...
05/09/2024 13:17:12

Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and qual...

100-invested-in-ascendis-pharma-15-years-ago-would-be-worth-this-much-today
$100 Invested In Ascendis Pharma 15 Years ...
05/06/2024 18:00:40

wells-fargo-maintains-overweight-on-ascendis-pharma-raises-price-target-to-262
Wells Fargo Maintains Overweight on Ascend...
05/03/2024 18:03:02

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from...

jp-morgan-maintains-overweight-on-ascendis-pharma-raises-price-target-to-170
JP Morgan Maintains Overweight on Ascendis...
05/03/2024 15:19:08

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $16...

cantor-fitzgerald-reiterates-overweight-on-ascendis-pharma-maintains-173-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/03/2024 14:59:37

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.

ascendis-pharma-q1-sales-95894m-beat-79492m-estimate
Ascendis Pharma Q1 Sales €95.894M Beat €79...
05/02/2024 20:46:03

looking-into-ascendis-pharmas-recent-short-interest
Looking Into Ascendis Pharma's Recent Shor...
04/26/2024 15:30:29

mhra-approves-yorvipath-in-great-britain-for-adults-with-chronic-hypoparathyroidism
MHRA Approves YORVIPATH In Great Britain F...
04/24/2024 12:31:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)